Companies: 10,795·Total market cap: $144.5T
Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGLNASDAQHealthcare● Active
$486.98
$-5.85(-1.19%)
Market Cap$11.2B
P/E Ratio
52W High$615
52W Low$271.96
Overview

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · MDGL · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-12.80mdgl eps ttm · mdgl earnings per shareEarnings history
PE Ratio (TTM)mdgl pe ratio ttm · mdgl price to earningsPE Ratio deep dive
Revenue (TTM)$1.1Bmdgl revenue ttm · mdgl annual revenueFull revenue history
Dividend YieldNo Dividenddoes mdgl pay dividends · mdgl dividend yieldDividend history
Shares Outstanding22.4Mmdgl shares outstanding · mdgl floatShares outstanding history
Next EarningsAug 4, 2026Est.mdgl earnings date · mdgl next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$958.4M▲ +432.05% YoY
202320242025
madrigal pharmaceuticals, inc. revenue · mdgl revenue 2025
FY 2025Net Income-$288.3M▲ +38.12% YoY
202320242025
madrigal pharmaceuticals, inc. net income · mdgl profit 2025
FY 2025EPS$-12.85▲ +41.32% YoY
202320242025
mdgl eps · madrigal pharmaceuticals, inc. earnings per share 2025
TTM:Revenue: $1.13BNet Income: -$309.4MEPS: $-12.80View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy23 analystsis mdgl a buy · mdgl analyst rating
Strong Buy
0
Buy
20
Hold
2
Sell
1
Strong Sell
0
12-Month Price Target
$571.00Low
$486.98Current
$731.25Avg Target50.16% upside
$964.00High
mdgl price target · mdgl 12 month forecast

Total: 23 · Buy rate: 87.0%

The MDGL analyst consensus is Buy, based on ratings from 23 Wall Street analysts over the past 3 months. The average 12-month price target is $731.25, representing +50.16% upside from the current price of $486.98.

Stock Performance

Full History
1D-1.19%
1W+8.07%
1M-4.52%
3M+12.51%
YTD-16.38%
1Y+73.77%
5Y+360.85%

About Madrigal Pharmaceuticals, Inc.

CEOWilliam J. Sibold
IPO DateFeb 6, 2007
Employees528
CountryUS

Madrigal Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, a…

what is madrigal pharmaceuticals, inc. · mdgl stock overview · madrigal pharmaceuticals, inc. company profile · who is madrigal pharmaceuticals, inc. ceo · mdgl NASDAQ · madrigal pharmaceuticals, inc. headquarters · madrigal pharmaceuticals, inc. business segments

About Stock Overview & Key Data

Madrigal Pharmaceuticals, Inc. (MDGL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 6, 2007. As of the latest trading session, MDGL stock price is $486.98, with a market capitalization of $11.2B. The stock has returned +73.77% over the past 12 months and -16.38% year-to-date.

According to 23 Wall Street analysts, the consensus rating for Madrigal Pharmaceuticals, Inc. stock is Buy, with an average 12-month price target of $731.25. In fiscal year 2025, Madrigal Pharmaceuticals, Inc. reported revenue of $958.4M and net income of -$288.3M. For detailed data — including Madrigal Pharmaceuticals, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Madrigal Pharmaceuticals, Inc. (MDGL) stock price is $486.98. The stock is traded on NASDAQ under the ticker symbol MDGL. The 52-week range is $271.96 – $615.00.

MDGL stock priceMDGL quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice